{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:37:00Z","timestamp":1781811420488,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-023-00464-0","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T16:36:31Z","timestamp":1684859791000},"page":"107-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cardiac safety profile of type II kinase inhibitors: Analysis of post-marketing reports from databases of European Medicine Agency & World Health Organization"],"prefix":"10.1007","volume":"31","author":[{"given":"Atul","family":"Khurana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6107-7162","authenticated-orcid":false,"given":"Mandeep Kumar","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harikesh","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"issue":"5","key":"464_CR1","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.3390\/ijms23052815","volume":"23","author":"A Grela-Wojewoda","year":"2022","unstructured":"Grela-Wojewoda A, Pacholczak-Madej R, Adamczyk A, Korman M, P\u00fcsk\u00fcll\u00fco\u011flu M. Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. Int J Mol Sci. 2022;23(5):2815. https:\/\/doi.org\/10.3390\/ijms23052815.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"464_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"464_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","volume":"33","author":"SD Lamore","year":"2020","unstructured":"Lamore SD, Kohnken RA, Peters MF, Kolaja KL. Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches. Chem Res Toxicol. 2020;33(1):125\u201336. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00387.","journal-title":"Chem Res Toxicol"},{"key":"464_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16442","author":"PY Lee","year":"2022","unstructured":"Lee PY, Yeoh Y, Low TY. A recent update on small-molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry-based proteomic analysis. FEBS J. 2022. https:\/\/doi.org\/10.1111\/febs.16442.","journal-title":"FEBS J"},{"issue":"11","key":"464_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3389\/fphar.2020.00891","volume":"12","author":"Y Jin","year":"2020","unstructured":"Jin Y, Xu Z, Yan H, He Q, Yang X, Luo P. A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Front Pharmacol. 2020;12(11):891. https:\/\/doi.org\/10.3389\/fphar.2020.00891.","journal-title":"Front Pharmacol"},{"issue":"9","key":"464_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","volume":"44","author":"A Mascolo","year":"2021","unstructured":"Mascolo A, Scavone C, Ferrajolo C, Rafaniello C, Danesi R, Del Re M, et al. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. Drug Saf. 2021;44(9):957\u201371. https:\/\/doi.org\/10.1007\/s40264-021-01086-8.","journal-title":"Drug Saf"},{"key":"464_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-020-00185-z","volume":"9","author":"L Ning","year":"2020","unstructured":"Ning L, Hu C, Lu P, et al. Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study. Exp Hematol Oncol. 2020;9:29. https:\/\/doi.org\/10.1186\/s40164-020-00185-z.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"464_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1055-9965.epi-14-1002","volume":"24","author":"GL Ma","year":"2015","unstructured":"Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev. 2015;24(1):298\u2013302. https:\/\/doi.org\/10.1158\/1055-9965.epi-14-1002.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"464_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79\u201387. https:\/\/doi.org\/10.14740\/wjon1279.","journal-title":"World J Oncol"},{"key":"464_CR10","doi-asserted-by":"publisher","first-page":"675811","DOI":"10.3389\/fphys.2021.675811","volume":"12","author":"M Santoro","year":"2021","unstructured":"Santoro M, Mancuso S, Accurso V, Di Lisi D, Novo G, Siragusa S. Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review. Front Physiol. 2021;12:675811. https:\/\/doi.org\/10.3389\/fphys.2021.675811.","journal-title":"Front Physiol"},{"issue":"3","key":"464_CR11","doi-asserted-by":"publisher","first-page":"1801797","DOI":"10.1183\/13993003.01797-2018","volume":"54","author":"I Noth","year":"2019","unstructured":"Noth I, Wijsenbeek M, Kolb M, Bonella F, Moros L, Wachtlin D, et al. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. Eur Respir J. 2019;54(3):1801797. https:\/\/doi.org\/10.1183\/13993003.01797-2018.","journal-title":"Eur Respir J"},{"issue":"11","key":"464_CR12","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3389\/fphar.2020.00830","volume":"9","author":"R Ruggiero","year":"2020","unstructured":"Ruggiero R, Fraenza F, Scavone C, di Mauro G, Piscitelli R, Mascolo A, et al. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Front Pharmacol. 2020;9(11):830. https:\/\/doi.org\/10.3389\/fphar.2020.00830.","journal-title":"Front Pharmacol"},{"issue":"5","key":"464_CR13","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/cancers13051131","volume":"13","author":"R Noseda","year":"2021","unstructured":"Noseda R, Bonaldo G, Motola D, Stathis A, Ceschi A. Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase. Cancers (Basel). 2021;13(5):1131. https:\/\/doi.org\/10.3390\/cancers13051131.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"464_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","volume":"14","author":"E Raschi","year":"2019","unstructured":"Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, et al. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. Target Oncol. 2019;14(2):205\u201321. https:\/\/doi.org\/10.1007\/s11523-019-00632-w.","journal-title":"Target Oncol"},{"issue":"10","key":"464_CR15","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23(10):e333\u2013465.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"464_CR16","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","volume":"12","author":"S Cirmi","year":"2020","unstructured":"Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers (Basel). 2020;12(4):826. https:\/\/doi.org\/10.3390\/cancers12040826.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"464_CR17","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00432-021-03521-w","volume":"147","author":"W Hou","year":"2021","unstructured":"Hou W, Ding M, Li X, Zhou X, Zhu Q, Varela-Ramirez A, et al. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2021;147(8):2407\u201320. https:\/\/doi.org\/10.1007\/s00432-021-03521-w.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"48","key":"464_CR18","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889\u201397. https:\/\/doi.org\/10.1093\/eurheartj\/ehz766.","journal-title":"Eur Heart J"},{"issue":"1","key":"464_CR19","doi-asserted-by":"publisher","first-page":"100338","DOI":"10.1016\/j.esmoop.2021.100338","volume":"7","author":"P Vallerio","year":"2022","unstructured":"Vallerio P, Orenti A, Tosi F, Maistrello M, Palazzini M, Cingarlini S, et al. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO Open. 2022;7(1):100338. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100338.","journal-title":"ESMO Open"},{"issue":"13","key":"464_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/vhrm.s108874","volume":"4","author":"N Aghel","year":"2017","unstructured":"Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017;4(13):293\u2013303. https:\/\/doi.org\/10.2147\/vhrm.s108874.","journal-title":"Vasc Health Risk Manag"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-023-00464-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-023-00464-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-023-00464-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T09:30:28Z","timestamp":1699003828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-023-00464-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1007\/s40199-023-00464-0","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"25 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Safety data retrieved from the spontaneous reporting process are anonymous and concur with ethical standards. Therefore, there was no further requirement for the ethical measure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}